Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Circulating Endotoxin as a Contributing Inflammatory Mediator in Osteoporosis Risk and its Association with Vitamin D Deficiency | National Plan for Science and Technology | Ongoing | Vitamin D3 VS. Alendronate | 3 | 11-MED-2113-02 or (G1109-665) | KFMC |
| Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial | King Abdullah Medical City, Makkah | Ongoing | VITAMIN D3 (CHOLECALCIFEROL) | 3 | IRB#16-252, V2 | KAMC |
| Bi-weekly Cetuximab and XELIRI(Capecitabine and Irinotecan) as first line therapy in K/N-RAS wild type advanced colorectal cancer: Phase I-II CETUXIRI study | King Faisal Specialist Hospital and Research Centre | Completed | Cetuximab | 1/2 | 1 , 29/07/2015 | KFSH&RC-R |
| Autologous Bone marrow derived osteoblasts in the Management of Avascular Necrosis of the Head of Femur: A Phase II | PI initiated | Rejected | Osteoblasts Stem cells | 2 | 2018-01-315 | King Fahad University Hospital (Al-Khobar) |
| Autologous Bone Marrow Derived Chondrocytes in the Management of Osteoarthritis of Knee: A Phase II Clinical Trial. | PI initiated | Rejected | Chondrocytes Stemcells | 2 | 2018-01-314 | King Fahad University Hospital (Al-Khobar) |
| Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers, An International, Multicenter, Double Blind, Randomized Placebo Controlled Phase 3 trial (ICR-02/ASCOLT) | King Fahad Medical City | Completed | Aspirin | 3 | ICR-02/ASCOLT | KFMC |
| An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" | Novartis | Completed | TKI258 / Sorafenib | 3 | CTKI258A2302 | KFSH & RC-R |
| An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE). | Novartis | Rejected | RAD001 (Everolimus) | 2 | CRAD001LIC01 | KFSH & RC-R |
| An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). | Novartis | Completed | INC424 (ruxolitinib) | 3b | CINC424A2401 | NGHA-R |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Roche | Terminated | Ocrelizumab | 3b | MN39159 | KFSH&RC-R |